Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Beijing GoBroad Boren Hospital, Beijing, Beijing Municipality Peking University Cancer Hospital & Institute, Beijing, Beijing Municipality Henan Cancer Hospital, Zhengzhou